Katrin Ritzel1, Felix Beuschlein1, Christina Berr1, Andrea Osswald1, Nicole Reisch1, Martin Bidlingmaier1, Harald Schneider1, Jürgen Honegger1, Lucas L Geyer1, Jochen Schopohl1, Martin Reincke2. 1. Medizinische Klinik und Poliklinik IVKlinikum der Universität München, Ziemssenstraße 1, D-80336 Munich, GermanyDepartment of NeurosurgeryUniversity of Tuebingen, Tuebingen, GermanyInstitut für klinische RadiologieKlinikum der Ludwig-Maximilians-Universität München, Munich, Germany. 2. Medizinische Klinik und Poliklinik IVKlinikum der Universität München, Ziemssenstraße 1, D-80336 Munich, GermanyDepartment of NeurosurgeryUniversity of Tuebingen, Tuebingen, GermanyInstitut für klinische RadiologieKlinikum der Ludwig-Maximilians-Universität München, Munich, Germany Martin.Reincke@med.uni-muenchen.de.
Abstract
OBJECTIVE: The aim of the present study was to validate criteria of corticotropin-releasing hormone (CRH) stimulation and 8 mg dexamethasone suppression (high-dose dexamethasone suppression, HDDS) to distinguish the etiology of ACTH-dependent Cushing's syndrome. SUBJECTS AND METHODS: We retrospectively analyzed cortisol and ACTH after the injection of 100 μg human CRH in confirmed Cushing's disease (CD, n=78) and confirmed ectopic Cushing's syndrome (ECS, n=18). Cortisol and ACTH increase (in percentage above basal (%B)) at each time point, maximal increase (Δmax %B), and area under the curve (AUC %B) were analyzed using receiver operator characteristics (ROC) curve analyses. Cortisol suppression (%B) after 8 mg of dexamethasone was evaluated as a supplementary criterion. RESULTS: An increase in ACTH of ≥ 43%B at 15 min after CRH was the strongest predictor of CD, with a positive likelihood ratio of 14.0, a sensitivity of 83%, a specificity of 94%, a positive predictive value of 98% and a negative predictive value of 58%. All of the other criteria of stimulated ACTH and cortisol levels were not superior in predicting CD in response to CRH injection. The addition of cortisol suppression by dexamethasone did not increase the discriminatory power. However, the combination of a positive ACTH response at 15 min and a positive HDDS test excluded ECS in all cases. CONCLUSION: The present findings support the use of plasma ACTH levels 15 min after the injection of human CRH as a response criterion for distinguishing between CD and ECS. The addition of the HDDS test is helpful for excluding ECS when both tests are positive.
OBJECTIVE: The aim of the present study was to validate criteria of corticotropin-releasing hormone (CRH) stimulation and 8 mg dexamethasone suppression (high-dose dexamethasone suppression, HDDS) to distinguish the etiology of ACTH-dependent Cushing's syndrome. SUBJECTS AND METHODS: We retrospectively analyzed cortisol and ACTH after the injection of 100 μg humanCRH in confirmed Cushing's disease (CD, n=78) and confirmed ectopic Cushing's syndrome (ECS, n=18). Cortisol and ACTH increase (in percentage above basal (%B)) at each time point, maximal increase (Δmax %B), and area under the curve (AUC %B) were analyzed using receiver operator characteristics (ROC) curve analyses. Cortisol suppression (%B) after 8 mg of dexamethasone was evaluated as a supplementary criterion. RESULTS: An increase in ACTH of ≥ 43%B at 15 min after CRH was the strongest predictor of CD, with a positive likelihood ratio of 14.0, a sensitivity of 83%, a specificity of 94%, a positive predictive value of 98% and a negative predictive value of 58%. All of the other criteria of stimulated ACTH and cortisol levels were not superior in predicting CD in response to CRH injection. The addition of cortisol suppression by dexamethasone did not increase the discriminatory power. However, the combination of a positive ACTH response at 15 min and a positive HDDS test excluded ECS in all cases. CONCLUSION: The present findings support the use of plasma ACTH levels 15 min after the injection of humanCRH as a response criterion for distinguishing between CD and ECS. The addition of the HDDS test is helpful for excluding ECS when both tests are positive.
Authors: Maria Fleseriu; Richard Auchus; Irina Bancos; Anat Ben-Shlomo; Jerome Bertherat; Nienke R Biermasz; Cesar L Boguszewski; Marcello D Bronstein; Michael Buchfelder; John D Carmichael; Felipe F Casanueva; Frederic Castinetti; Philippe Chanson; James Findling; Mônica Gadelha; Eliza B Geer; Andrea Giustina; Ashley Grossman; Mark Gurnell; Ken Ho; Adriana G Ioachimescu; Ursula B Kaiser; Niki Karavitaki; Laurence Katznelson; Daniel F Kelly; André Lacroix; Ann McCormack; Shlomo Melmed; Mark Molitch; Pietro Mortini; John Newell-Price; Lynnette Nieman; Alberto M Pereira; Stephan Petersenn; Rosario Pivonello; Hershel Raff; Martin Reincke; Roberto Salvatori; Carla Scaroni; Ilan Shimon; Constantine A Stratakis; Brooke Swearingen; Antoine Tabarin; Yutaka Takahashi; Marily Theodoropoulou; Stylianos Tsagarakis; Elena Valassi; Elena V Varlamov; Greisa Vila; John Wass; Susan M Webb; Maria C Zatelli; Beverly M K Biller Journal: Lancet Diabetes Endocrinol Date: 2021-10-20 Impact factor: 32.069
Authors: Jordan E Perlman; Philip C Johnston; Ferdinand Hui; Guy Mulligan; Robert J Weil; Pablo F Recinos; Divya Yogi-Morren; Roberto Salvatori; Debraj Mukherjee; Gary Gallia; Laurence Kennedy; Amir H Hamrahian Journal: J Clin Endocrinol Metab Date: 2021-04-23 Impact factor: 5.958
Authors: O Polat Korkmaz; B Karayel; M Korkmaz; O Haliloglu; S Sahin; E Durcan; M M Oren; P Kadioglu Journal: Acta Endocrinol (Buchar) Date: 2019 Apr-Jun Impact factor: 0.877
Authors: E Ferrante; M Barbot; A L Serban; F Ceccato; G Carosi; L Lizzul; E Sala; A Daniele; R Indirli; M Cuman; M Locatelli; R Manara; M Arosio; M Boscaro; G Mantovani; C Scaroni Journal: J Endocrinol Invest Date: 2021-10-26 Impact factor: 4.256